Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

SubQ Amivantamab Q4W Maintains Efficacy, Improves Convenience: Nicolas Girard, MD, PhD

Summary by ajmc.com
The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

ajmc.comajmc.com

SubQ Amivantamab Q4W Maintains Efficacy, Improves Convenience: Nicolas Girard, MD, PhD

The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ajmc.com broke the news in on Saturday, September 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Healthcare icon

Healthcare

Maryland icon

Maryland

News
For You
SearchBlindspotLocal